Rezdiffra reduces liver scarring in high-risk MASH patients: Trial data
Long-term treatment with Rezdiffra (resmetirom) reduces liver scarring and other signs of advanced disease in adults with high-risk compensated cirrhosis due to metabolic dysfunction-associated steatohepatitis…